Kiniksa Pharmaceuticals International, plc
KNSA
$40.59
$0.521.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.44M | 17.83M | 8.54M | -8.89M | -12.69M |
| Total Depreciation and Amortization | 384.00K | 358.00K | 345.00K | 400.00K | 399.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.88M | 11.57M | 11.84M | 6.72M | 4.45M |
| Change in Net Operating Assets | -1.02M | -1.67M | 1.60M | 20.54M | 5.60M |
| Cash from Operations | 33.68M | 28.09M | 22.32M | 18.77M | -2.24M |
| Capital Expenditure | -671.00K | -165.00K | -99.00K | -193.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.08M | -3.72M | -51.44M | 65.49M | -6.35M |
| Cash from Investing | -62.76M | -3.88M | -51.54M | 65.29M | -6.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.25M | 12.75M | 3.18M | 2.72M | 9.40M |
| Repurchase of Common Stock | -4.35M | -2.05M | -412.00K | -578.00K | -2.71M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11.90M | 10.70M | 2.77M | 2.14M | 6.69M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.18M | 34.91M | -26.45M | 86.21M | -1.90M |